Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | MRD: the most relevant prognostic factor in myeloma

Bruno Paiva • 15 May 2020
COMy Virtual 2020
Multiple Myeloma

Following his talk at the 2020 COMy virtual meeting, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses which patient with multiple myeloma should undergo measurable residual disease (MRD) monitoring, the rapid growth of the technique and it’s increasing importance. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Bruno Paiva

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
2:08
Minimally invasive assessment of MRD in multiple myeloma
Bruno Paiva • 9 Dec 2023
2:34
Mutant hematopoietic progenitor cells in MM associated with secondary primary malignancies
Bruno Paiva • 9 Dec 2023
1:52
Clinical significance of MRD status in patients with MM treated with CAR-T and T-cell engagers
Bruno Paiva • 9 Dec 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals